Frontiers in Immunology (Sep 2021)

Human Chorionic Gonadotropin and Related Peptides: Candidate Anti-Inflammatory Therapy in Early Stages of Sepsis

  • Sun Koo Yoo,
  • Syed Faizan Mehdi,
  • Suma Pusapati,
  • Nimisha Mathur,
  • Manasa Anipindi,
  • Bruno Lunenfeld,
  • Barbara Lowell,
  • Huan Yang,
  • Christine Noel Metz,
  • Sawleha Arshi Khan,
  • Derek Leroith,
  • Jesse Roth

DOI
https://doi.org/10.3389/fimmu.2021.714177
Journal volume & issue
Vol. 12

Abstract

Read online

Sepsis continues to be a major cause of morbidity, mortality, and post-recovery disability in patients with a wide range of non-infectious and infectious inflammatory disorders, including COVID-19. The clinical onset of sepsis is often marked by the explosive release into the extracellular fluids of a multiplicity of host-derived cytokines and other pro-inflammatory hormone-like messengers from endogenous sources (“cytokine storm”). In patients with sepsis, therapies to counter the pro-inflammatory torrent, even when administered early, typically fall short. The major focus of our proposed essay is to promote pre-clinical studies with hCG (human chorionic gonadotropin) as a potential anti-inflammatory therapy for sepsis.

Keywords